Zevra Therapeutics, Inc. (ZVRA) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin 78.2%, revenue growth 53.3% YoY, P/E 12.2. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $106.47M |
| Revenue (TTM) | $0.1B |
| Net Margin | 78.2% |
| Return on Equity | 26.8% |
| Operating Margin (TTM) | 60.5% |
| Current Ratio | 5.17 |
| Net Debt / EBITDA | -0.0 |
| Interest Coverage | 14.4 |
| Revenue Growth (YoY) | 53.3% |
| EPS Growth (YoY) | -88.7% |
| FCF Growth (YoY) | -540.9% |
| P/E Ratio | 12.2 |
| EV / EBITDA | 6.7 |
| Price / Book | 3.26 |
| Price / Sales | 5.22 |
| FCF Yield | 4.6% |
| Altman Z-Score | 1.60 (distress) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
ZVRA overview · ZVRA earnings · ZVRA KPIs · ZVRA documents · ZVRA ownership · ZVRA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.